Does the media refer more to TILS or COIL?

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Roquefort Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.18 beat Roquefort Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roquefort Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, COIL or VSN?

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roquefort Therapeutics N/A N/A -£1.52M -£21.90 N/A Verseon N/A N/A N/A -£14.30 N/A

Does the media favor COIL or SCLP?

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Roquefort Therapeutics and 1 mentions for Scancell. Scancell's average media sentiment score of 0.75 beat Roquefort Therapeutics' score of 0.00 indicating that Scancell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roquefort Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scancell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, COIL or MPH?

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roquefort Therapeutics N/A N/A -£1.52M -£21.90 N/A Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A

Do analysts rate 4BB or COIL?

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 152.25%. Given 4basebio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 4basebio is more favorable than Roquefort Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Roquefort Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Roquefort Therapeutics (COIL) Competitors

GBX 8.50 +0.90 (+11.84%)

As of 09:58 AM Eastern

Compare

COIL vs. TILS, VSN, SCLP, MPH, and 4BB

Should you buy Roquefort Therapeutics stock or one of its competitors? Roquefort Therapeutics's main competitors and comparable companies include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Roquefort Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.18 beat Roquefort Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roquefort Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tiziana Life Sciences has higher earnings, but lower revenue than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

1.8% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tiziana Life Sciences beats Roquefort Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Roquefort Therapeutics (LON:COIL) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Roquefort Therapeutics had 2 more articles in the media than Verseon. MarketBeat recorded 2 mentions for Roquefort Therapeutics and 0 mentions for Verseon. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company	Overall Sentiment
Roquefort Therapeutics	Neutral
Verseon	Neutral

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
Verseon	N/A	N/A	N/A

1.8% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

Summary

Roquefort Therapeutics and Verseon tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Scancell?

Roquefort Therapeutics (LON:COIL) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Scancell has a net margin of -116.98% compared to Roquefort Therapeutics' net margin of -57,057.07%. Scancell's return on equity of 90.29% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
Scancell	-116.98%	90.29%	-45.28%

Roquefort Therapeutics has higher earnings, but lower revenue than Scancell. Scancell is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
Scancell	£4.71M	22.27	-£6.75M	-£0.55	N/A

1.8% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Comparatively, 13.2% of Scancell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Roquefort Therapeutics and 1 mentions for Scancell. Scancell's average media sentiment score of 0.75 beat Roquefort Therapeutics' score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roquefort Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market. Comparatively, Scancell has a beta of 0.687, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Roquefort Therapeutics and Scancell tied by winning 6 of the 12 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Roquefort Therapeutics (LON:COIL) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A

In the previous week, Roquefort Therapeutics had 2 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 2 mentions for Roquefort Therapeutics and 0 mentions for Mereo BioPharma Group plc (MPH.L). Roquefort Therapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company	Overall Sentiment
Roquefort Therapeutics	Neutral
Mereo BioPharma Group plc (MPH.L)	Neutral

1.8% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Roquefort Therapeutics and Mereo BioPharma Group plc (MPH.L) tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to 4basebio?

4basebio (LON:4BB) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 152.25%. Given 4basebio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 4basebio is more favorable than Roquefort Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Roquefort Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Roquefort Therapeutics had 2 more articles in the media than 4basebio. MarketBeat recorded 2 mentions for Roquefort Therapeutics and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
Roquefort Therapeutics	Neutral

4basebio has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

0.9% of 4basebio shares are held by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Roquefort Therapeutics has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	50.76	-£9.84M	-£109.00	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

4basebio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

Summary

Roquefort Therapeutics beats 4basebio on 8 of the 14 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COIL vs. The Competition

Export

Metric	Roquefort Therapeutics	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£36.28M	£3.90B	£7.26B	£2.89B
Dividend Yield	N/A	3.64%	2.53%	6.22%
P/E Ratio	-0.39	14.12	274.69	366.69
Price / Sales	N/A	1,424.45	647.76	90,195.94
Price / Cash	1.49	41.62	28.04	27.89
Price / Book	2.23	15.60	10.56	6.37
Net Income	-£1.52M	-£22.86M	£3.49B	£5.89B
7 Day Performance	13.44%	-1.25%	-0.23%	1.00%
1 Month Performance	-8.60%	-4.56%	-2.80%	-0.05%
1 Year Performance	-54.67%	38.32%	18.25%	19.57%

Roquefort Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COIL Roquefort Therapeutics	N/A	GBX 8.50 +11.8%	N/A	-59.5%	£36.28M	N/A	N/A	9	News Coverage Analyst Forecast Gap Up
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11	News Coverage
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up
SCLP Scancell	N/A	GBX 9.84 -0.1%	N/A	-2.3%	£105.07M	£4.71M	N/A	51
MPH Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	N/A	£89.76M	N/A	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roquefort Therapeutics (COIL) Competitors

COIL vs. TILS, VSN, SCLP, MPH, and 4BB

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Summary

How does Roquefort Therapeutics compare to Verseon?

Summary

How does Roquefort Therapeutics compare to Scancell?

Summary

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Summary

How does Roquefort Therapeutics compare to 4basebio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COIL vs. The Competition

Roquefort Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roquefort Therapeutics (COIL) Competitors

COIL vs. TILS, VSN, SCLP, MPH, and 4BB

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Does the media refer more to TILS or COIL?

Which has stronger earnings & valuation, TILS or COIL?

Is TILS or COIL more profitable?

Do insiders & institutionals believe in TILS or COIL?

Summary

How does Roquefort Therapeutics compare to Verseon?

Does the media refer more to COIL or VSN?

Is COIL or VSN more profitable?

Do institutionals & insiders have more ownership in COIL or VSN?

Which has higher valuation & earnings, COIL or VSN?

Summary

How does Roquefort Therapeutics compare to Scancell?

Is COIL or SCLP more profitable?

Which has better valuation and earnings, COIL or SCLP?

Do insiders & institutionals believe in COIL or SCLP?

Does the media favor COIL or SCLP?

Which has more risk & volatility, COIL or SCLP?

Summary

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Which has better valuation & earnings, COIL or MPH?

Is COIL or MPH more profitable?

Does the media prefer COIL or MPH?

Do insiders & institutionals have more ownership in COIL or MPH?

Summary

How does Roquefort Therapeutics compare to 4basebio?

Do analysts rate 4BB or COIL?

Does the media refer more to 4BB or COIL?

Is 4BB or COIL more profitable?

Do insiders & institutionals hold more shares of 4BB or COIL?

Which has higher valuation and earnings, 4BB or COIL?

Which has more volatility and risk, 4BB or COIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COIL vs. The Competition

Roquefort Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools